Bicuspid aortic valve
Conditions
Interventions
BAV Pathology Group (Cross-sectional Study):None
TAV Pathology Group (Cross-sectional Study):None
BAV Cohort (Cohort Study):None
TAV Cohort (Cohort Study):None
BAV CTA Cohort:None
TAV CTA Cohort:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Cross-sectional Study Participants diagnosed with ''bicuspid aortic valve (BAV)'' from the echocardiography database were retrospectively included, and their initial ltrasound records were extracted. Based on the presence or absence of valvular and ascending aortic pathologies, they were divided into a pathology group and a non-pathology group, with a ratio of approximately 7:1. Furthermore, early-stage pathology participants (mild or moderate pathologies) from the pathology group were identified. Using a greedy matching algorithm, tricuspid aortic valve (TAV) outpatients with early-stage pathologies (mild or moderate) were matched 1:1 based on gender, type and severity of aortic valve disease, and ascending aortic diameter through propensity score matching. 2. Cohort Study BAV Group Participants with BAV and documented aortic valve or ascending aortic pathology from the echocardiography database, who had multiple ultrasound visits with intervals exceeding 1year, were included. Participants with computed tomography angiography (CTA) and a necessity for CTA follow-up (e.g., dilated ascending aorta, coronary artery disease, post-non-valvular cardiac surgery) were selected for the CTA follow-up cohort. Control group Based on the categories and severity of aortic valve and ascending aortic pathologies, as well as sex, propensity score matching was performed using a greedy matching algorithm in a 1:1 ratio to select TAV participants as the control group for this cohort study.
Exclusion criteria
Exclusion criteria: 1. Age below 18 years; 2. Presence of other congenital heart diseases; 3. Prior structural heart surgery; 4. Primary pathologies of the mitral or tricuspid valves; 5. Infective endocarditis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical endpoint indicators (All-cause mortality, cardiac mortality, surgical intervention, and rehospitalization); | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiography-related indicators (peak transvalvular velocity, mean transvalvular pressure gradient, and other cardiac structural and hemodynamic parameters);CT-related indicators (valvular calcification, fibrosis, etc.) ;Symptoms and newly developed comorbidities;Laboratory blood test indicators (including but not limited to liver function tests, renal function tests, lipid panels, etc.); | — |
Countries
China
Contacts
Public ContactOu Yuanweixiang
West China Hospital of Sichuan University
Outcome results
None listed